The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Bortezomib-induced immunogenic cell death in myeloma
Kenneth Anderson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the findings of a study investigating the mode of action of bortezomib, a proteasome inhibitor, in multiple myeloma. Cell culture analyses showed that bortezomib induces immunogenic cell death of myeloma cells. Calreticulin (CALR) was identified as having a critical role in bortezomib-induced immunogenicity. RNAseq experiments were conducted on bortezomib-treated versus untreated tumors and showed that a specific ICD signature was associated with bortezomib use and that increased expression of this signature was strongly correlated with positive clinical outcomes. It was found that bortezomib induced a type-1-interferon ICD response via cGAS/STING pathway activation. STING activation induced potent anti-myeloma activity, suggesting STING agonists may be beneficial in myeloma. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
